Don't worry. They won't R\S until they max the AS. They may play a few more PRs to help that along so there may be good opportunities to recover losses. This one seems to be working pretty well. Of course, there is always that tendency to look over-pumped and not attract comparable volume the next time, or the time after that. These things take a very long time to realize profits so there may be many chances to play it as the company claws away at survival. Perhaps big pharma cos. will be interested but they have plenty of time on their sides.
Too many interesting places to park money for long term investments to get tied up by an untested treatment, IMO. "Flip it and watch it but don't hold overnight.", is a good rule with these early stage drugs. Go with what you know, not speculation about some mysterious rumor of interest.
News 
Market Data 
Discover 
AI
